MedPath

Estimating prognosis of patients with liver disease based on blood parameters

Phase 3
Conditions
Health Condition 1: K740- Hepatic fibrosis
Registration Number
CTRI/2021/09/036283
Lead Sponsor
SELFDR ISHITA GUPTA
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

All patients aged >= 18 years admitted at Kasturba

Hospital with the confirmed diagnosis of liver cirrhosis of any underlying etiology will be included in the study.

Exclusion Criteria

Patients aged <18 years

Co-existence of hepatocellular carcinoma or other malignant tumour

Patients with haematological malignancy and autoimmune disease

Patients with acquired immunodeficiency syndrome

Patients presenting with any kind of infections such as tuberculosis will also excluded from the study.

Study & Design

Study Type
Observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
ymphocte monocyte ratio as an independent, cost effective tools to predict severity of disease in liver cirrhosis patients.Timepoint: 1 YEAR
Secondary Outcome Measures
NameTimeMethod
MR as an independent indicator in inflammatory diseasesTimepoint: 1 YEAR
© Copyright 2025. All Rights Reserved by MedPath